Alimera Sciences, Inc. (ALIM)
- Previous Close
3.6300 - Open
3.6546 - Bid 3.2100 x 100
- Ask 3.4100 x 100
- Day's Range
3.2800 - 3.6546 - 52 Week Range
1.5600 - 4.3800 - Volume
25,165 - Avg. Volume
72,064 - Market Cap (intraday)
173.293M - Beta (5Y Monthly) 1.20
- PE Ratio (TTM)
-- - EPS (TTM)
-0.8400 - Earnings Date May 13, 2024 - May 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
8.00
Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.
alimerasciences.com154
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: ALIM
Performance Overview: ALIM
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ALIM
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ALIM
Valuation Measures
Market Cap
173.29M
Enterprise Value
226.55M
Trailing P/E
--
Forward P/E
109.89
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.05
Price/Book (mrq)
3.75
Enterprise Value/Revenue
2.81
Enterprise Value/EBITDA
-203.19
Financial Highlights
Profitability and Income Statement
Profit Margin
-24.93%
Return on Assets (ttm)
-1.23%
Return on Equity (ttm)
-158.76%
Revenue (ttm)
80.75M
Net Income Avi to Common (ttm)
-21.39M
Diluted EPS (ttm)
-0.8400
Balance Sheet and Cash Flow
Total Cash (mrq)
12.06M
Total Debt/Equity (mrq)
145.98%
Levered Free Cash Flow (ttm)
-80.36M
Research Analysis: ALIM
Company Insights: ALIM
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: ALIM
Daily – Vickers Top Insider Picks for 01/05/2022
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 01/04/2022
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 12/31/2021
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 12/30/2021
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.